Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro

British Journal of Pharmacology

Volumn 170, Issue 5, 2013, Pages 1041-1052

  Nielsen, Carsten Uhd ^a   Frolund S ^a   Abdulhadi, S ^a   Sari, H ^a   Langthaler, L ^a,b   Nohr M K ^a   Kall, M A ^b   Brodin, B ^a   Holm, R ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

gaboxadol; in vivo transporter; PAT1 (SLC36A1); sertraline; small intestinal absorption; transporter mediated pharmacokinetics

Indexed keywords

CARRIER PROTEIN; GABOXADOL; PROLINE; PROTON COUPLED AMINO ACID TRANSPORTER 1; PROTON COUPLED DI TRIPEPTIDE TRANSPORTER 1; SERTRALINE; SODIUM GLUCOSE COTRANSPORTER 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

GABOXADOL; IN VIVO TRANSPORTER; PAT1 (SLC36A1); SERTRALINE; SMALL INTESTINAL ABSORPTION; TRANSPORTER-MEDIATED PHARMACOKINETICS;

ADMINISTRATION, ORAL; AMINO ACID TRANSPORT SYSTEMS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CHROMATOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; ISOXAZOLES; MALE; PROLINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SODIUM-GLUCOSE TRANSPORTER 1; SYMPORTERS; TANDEM MASS SPECTROMETRY; XENOPUS LAEVIS;

EID: 84885644603     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12341     Document Type: Article

References (38)

1. Abbot EL, Grenade DS, Kennedy DJ, Gatfield KM, Thwaites DT, (2005). Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H(+)-coupled amino-acid transporter hPAT1. Br J Pharmacol 147: 298-306.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC) 5th edition. Br J Pharmacol 164: S1-S324.
3. Anderson CM, Grenade DS, Boll M, Foltz M, Wake KA, Kennedy DJ, et al. (2004). H+/amino acid transporter 1 (PAT1) is the imino acid carrier: an intestinal nutrient/drug transporter in human and rat. Gastroenterology 127: 1410-1422.
4. Broberg M, Holm R, Tonsberg H, Frolund S, Ewon KB, Nielsen A, et al. (2012). Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. Br J Pharmacol 167: 654-665.
5. Chen Z, Fei YJ, Anderson CM, Wake KA, Miyauchi S, Huang W, et al. (2003). Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. J Physiol 546: 349-361.
6. Chu XY, Liang Y, Cai X, Cuevas-Licea K, Rippley RK, Kassahun K, et al. (2009). Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters. Pharm Res 26: 459-468.
7. Ferrell JE, Jr, (1999). Xenopus oocyte maturation: new lessons from a good egg. Bioessays 21: 833-842.
8. Frolund S, Cutillas O, Larsen M, Brodin B, Nielsen CU, (2010a). Delta-aminolevulinic acid is a substrate for SLC36A1 (hPAT1). Br J Pharmacol 159: 1339-1353.
9. Frolund S, Holm R, Brodin B, Nielsen CU, (2010b). The proton-coupled amino acid transporter, SLC36A1 (hPAT1), transports Gly-Gly, Gly-Sar and other Gly-Gly mimetics. Br J Pharmacol 161: 589-600.
10. Frolund S, Langthaler L, Kall MA, Holm R, Nielsen CU, (2012). Intestinal drug transport via the proton-coupled amino acid transporter PAT1 (SLC36A1) is inhibited by Gly-X(aa) dipeptides. Mol Pharm 9: 2761-2769.
11. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, et al. (2008). Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 33: 277-286.
12. Haenisch B, Bonisch H, (2010). Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 381: 33-39.
13. Huang CJ, Kuo DH, Chang KH, Shieh P, Chen FA, Fang YC, et al. (2009). Effect of the antidepressant sertraline on Ca2+ fluxes in Madin-Darby canine renal tubular cells. J Recept Signal Transduct Res 29: 342-348.
14. Kall MA, Fu I, Dige T, Vallano P, Woolf E, Jorgensen M, (2007). Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. J Chromatogr B Analyt Technol Biomed Life Sci 858: 168-176.
15. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
16. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, et al. (2008). Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther 327: 432-441.
17. Larsen M, Larsen BB, Frolund B, Nielsen CU, (2008). Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci 35: 86-95.
18. Larsen M, Holm R, Jensen KG, Brodin B, Nielsen CU, (2009). Intestinal gaboxadol absorption via PAT1(SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol 157: 1380-1389.
19. Larsen M, Holm R, Jensen KG, Sveigaard C, Brodin B, Nielsen CU, (2010). 5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. Eur J Pharm Sci 39: 68-75.
20. Maertens C, Droogmans G, Verbesselt R, Nilius B, (2002). Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn Schmiedebergs Arch Pharmacol 366: 158-165.
21. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Metzner L, Kalbitz J, Brandsch M, (2004). Transport of pharmacologically active proline derivatives by the human proton-coupled amino acid transporter hPAT1. J Pharmacol Exp Ther 309: 28-35.
23. Metzner L, Kottra G, Neubert K, Daniel H, Brandsch M, (2005). Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J 19: 1468-1473.
24. Metzner L, Dorn M, Markwardt F, Brandsch M, (2009). The orally active antihyperglycemic drug beta-guanidinopropionic acid is transported by the human proton-coupled amino acid transporter hPAT1. Mol Pharm 6: 1006-1011.
25. Ming X, Knight BM, Thakker DR, (2011). Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm 8: 1677-1686.
26. Molnari JC, Hassan HE, Myers AL, (2012). Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Eur J Drug Metab Pharmacokinet 37: 57-63.
27. Obach RS, Cox LM, Tremaine LM, (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33: 262-270.
28. Ohno Y, Hibino H, Lossin C, Inanobe A, Kurachi Y, (2007). Inhibition of astroglial Kir4.1 channels by selective serotonin reuptake inhibitors. Brain Res 1178: 44-51.
29. Omkvist DH, Brodin B, Nielsen CU, (2010). Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen. Br J Pharmacol 161: 1793-1805.
30. Park KS, Kong ID, Park KC, Lee JW, (1999). Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med J 40: 144-151.
31. Pousti A, Bakhtiarian A, Najafi R, Deemyad T, Brumand K, Hosseini MJ, (2009). Effect of sertraline on ouabain-induced arrhythmia in isolated guinea-pig atria. Depress Anxiety 26: E106-E110.
32. Saruwatari J, Yasui-Furukori N, Niioka T, Akamine Y, Takashima A, Kaneko S, et al. (2012). Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol 32: 195-199.
33. Sawada K, Terada T, Saito H, Hashimoto Y, Inui K, (1999). Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol 128: 1159-1164.
34. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K, (2000). Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol 392: 11-17.
35. Thwaites DT, Anderson CM, (2006). Deciphering the mechanisms of intestinal imino (and amino) acid transport: the redemption of SLC36A1. Biochim Biophys Acta 1768: 179-197.
36. Thwaites DT, Anderson CM, (2011). The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. Br J Pharmacol 164: 1802-1816.
37. Zhu HJ, Appel DI, Grundemann D, Richelson E, Markowitz JS, (2012). Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res 65: 491-496.
38. Zhu T, Chen XZ, Steel A, Hediger MA, Smith DE, (2000). Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2. Pharm Res 17: 526-532.